EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSMMDG00005016286
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSMMDG00005001134
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSMMDG00005000859
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSMMDG00005023524
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSMMDG00005020925
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSMMDG00005023535
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSMMDG00005005372
Gene Symbol: PARP3
3 Cross references
198 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSMMDG00005020321
Gene Symbol: PORCN
1 Cross references
193 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSMMDG00005020335
Gene Symbol: PORCNL
1 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSMMDG00005012741
Gene Symbol: KCNMA1
1 Cross references
241 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSMMDG00005017628
Gene Symbol: KCNMA1
3 Cross references
235 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSMMDG00005022955
Gene Symbol: KCNK2B
1 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).